WallStreetZenWallStreetZen

NYSE: RDY
Dr Reddys Laboratories Ltd Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Dr Reddys Laboratories earnings were $657.6M for the trailing 12 months ending Mar 31, 2025, with -1.1% growth year over year. For the last reported fiscal year 2025 ending Mar 31, 2025, RDY reported annual earnings of $661.6M, with -1% growth. The next RDY earnings date is Oct 24, 2025.

RDY past earnings growth

How has RDY's earnings growth performed historically?

Company
-1.12%
Industry
28.3%
Market
29.72%
RDY's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
RDY's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
RDY's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

RDY earnings history

Current Revenue
$3.8B
Current Earnings
$661.6M
Current Profit Margin
17.4%
RDY's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

RDY Return on Equity

Current Company
18.4%
Current Industry
12.8%
Current Market
31.3%
RDY's Return on Equity (18.4%)... subscribe to Premium to read more.
High Return on Equity Performance

RDY undefined

Current Company
12.8%
Current Industry
6.9%
RDY is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when RDY announces earnings.

RDY undefined

Current Company
21.76%
Current Industry
14.3%
RDY has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RDY vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
RDY$1.12B$657.56M+20.54%$0.79
VTRS-$493.30M-$3.47BN/A-$2.90
NBIX$569.90M$348.30M+9.41%$3.48
ELAN$1.45B$434.00MN/A$0.88
RGC-$3.56M-$4.30MN/A-$0.01
View Top Pharmaceutical Stocks

RDY earnings dates

Next earnings date
Oct 24, 2025

Dr Reddys Laboratories Earnings Reports & History FAQ

What was RDY's earnings growth in the past year?

As of Dr Reddys Laboratories's earnings date in Invalid Date, Dr Reddys Laboratories's earnings has grown -1.12% year over year. This is 29.42 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 28.3%. RDY earnings in the past year totalled $657.56 million.

If you're new to stock investing, here's how to buy Dr Reddys Laboratories stock.

What are Dr Reddys Laboratories's earnings expectations?

The current EPS estimate for Dr Reddys Laboratories's earnings report in Invalid Date is $0.20.

When does Dr Reddys Laboratories report earnings?

The next RDY earnings call is Invalid Date. Add RDY to your watchlist to be reminded of Dr Reddys Laboratories's next earnings date.

Is Dr Reddys Laboratories profitable or losing money?

As of the last Dr Reddys Laboratories earnings report, Dr Reddys Laboratories is currently profitable. Dr Reddys Laboratories's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $661.64 million, a 0.96% decrease year over year.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.